Page last updated: 2024-08-22

camptothecin and oblimersen

camptothecin has been researched along with oblimersen in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Balsari, A; Carenini, N; De Cesare, M; Del Bufalo, D; Perego, P; Pratesi, G; Righetti, SC; Rivoltini, L; Zunino, F; Zupi, G	1
Burt, HM; Gleave, J; Gleave, ME; Jackson, JK	1
Berg, K; Hammond, LA; Izbicka, E; Kuhn, J; Mita, MM; Ochoa, L; Patnaik, A; Rowinsky, EK; Schwartz, G; Tolcher, AW; Yeh, IT	1

Trials

1 trial(s) available for camptothecin and oblimersen

Article	Year
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Irinotecan; Leukocytes, Mononuclear; Lymphopenia; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Oligonucleotides, Antisense; Thionucleotides	2006

Article

Year

A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.

Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:2

Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Irinotecan; Leukocytes, Mononuclear; Lymphopenia; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Oligonucleotides, Antisense; Thionucleotides

2006

Other Studies

2 other study(ies) available for camptothecin and oblimersen

Article	Year
Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts. European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:8 Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Proto-Oncogene Proteins c-bcl-2; Thionucleotides; Transplantation, Heterologous	2005
The inhibition of angiogenesis by antisense oligonucleotides to clusterin. Angiogenesis, 2005, Volume: 8, Issue:3 Topics: Apoptosis; Base Sequence; bcl-X Protein; Camptothecin; Cell Line; Cell Survival; Clusterin; Collagen; DNA Fragmentation; Doxorubicin; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Humans; Inhibitor of Apoptosis Proteins; Laminin; Microtubule-Associated Proteins; Neoplasm Proteins; Neovascularization, Pathologic; Oligonucleotides, Antisense; Paclitaxel; Proteoglycans; Survivin; Thionucleotides	2005

Article

Year

Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts.

European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:8

Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Proto-Oncogene Proteins c-bcl-2; Thionucleotides; Transplantation, Heterologous

2005

The inhibition of angiogenesis by antisense oligonucleotides to clusterin.

Angiogenesis, 2005, Volume: 8, Issue:3

Topics: Apoptosis; Base Sequence; bcl-X Protein; Camptothecin; Cell Line; Cell Survival; Clusterin; Collagen; DNA Fragmentation; Doxorubicin; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Humans; Inhibitor of Apoptosis Proteins; Laminin; Microtubule-Associated Proteins; Neoplasm Proteins; Neovascularization, Pathologic; Oligonucleotides, Antisense; Paclitaxel; Proteoglycans; Survivin; Thionucleotides

2005